UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 103

Harris, CM and G Scrivener (1996). Fundholders' prescribing costs: the first five years.
British Medical Journal , 313(7071), 1531-1534.
Hazlet, TK and DK Blough. (2002). Health services utilization with reference drug pricing
of histamine(2) receptor antagonists in British Columbia elderly. Medical Care , 40(8),
640-649.
Hillman, AL et al . (1999). Financial incentives and drug spending in managed care. Health
Affairs , 18(2), 189-200.
Hivon, M et al . (2005). Use of health technology assessment in decision making: corre-
sponsibility of users and producers? International Journal of Technology Assessment
in Health Care , 21(2), 268-275.
Hurley, J (1991). The effects of co-payments within drug reimbursement programs. Cana-
dian Public Policy , 17(4), 473-489.
Hurley, RE, JE Paul and DA Freund (1989). Going into gatekeeping: an empirical assess-
ment. QRB Quality Review Bulletin , 15(10), 306-314.
Huskamp, HA (2003). Managing psychotropic drug costs: will formularies work? Health
Affairs , 22(5), 84-96.
Huttin, C (1994). The use of prescription charges. Health Policy , 27(1), 53-73.
Huttin, C and J Andral (2000). How the reimbursement system may influence physicians'
decisions results from focus groups interviews in France. Health Policy , 54(2), 67-86.
Ioannides-Demos, LL, JE Ibrahim and JJ McNeil (2002). Reference-based pricing schemes:
effect on pharmaceutical expenditure, resource utilisation and health outcomes. Phar-
macoeconomics , 20(9), 577-591.
Jacobzone, S (2005). Pharmaceutical policies in OECD countries: reconciling social and
industrial goals. OECD Labour Market and Social Policy Occasional Papers, # 40.
Johnson, RE et al . (1997). The impact of increasing patient prescription drug cost sharing on
therapeutic classes of drugs received and on the health status of elderly HMO members.
Health Services Research , 32(1), 103-122.
Kanavos, P and J Costa-Font (2005). Pharmaceutical parallel trade in Europe: stakeholder
and competition effects. Economic Policy , 20 (44), 753-798.
Kanavos, P and E Mossialos (1999). Outstanding regulatory aspects in the European phar-
maceutical market. Pharmacoeconomics , 15(6), 519-533.
Kanavos, P and U Reinhardt (2003). Reference pricing for drugs: is it compatible with U.S.
health care? Health Affairs , 22(3), 16-30.
Kane, NM and RB Saltman (1997). Comparative experience in home care and pharmaceu-
tical policy. Health Policy , 41 (Suppl), S1-S7.
Koopmanschap, MA and FF Rutten (2003). The drug budget silo mentality: the Dutch case.
Value in Health , 6 (Suppl 1), S46-S51.
Kozma, CM, CE Reeder and EW Lingle (1990). Expanding medicaid drug formulary cov-
erage: effects on utilization of related services. Medical Care , 28(10), 963-977.
Kyle, M (2006a). Pharmaceutical price controls and entry strategies. Review of Economics
and Statistics , in press.
Kyle, M (2006b). The role of firm characteristics in pharmaceutical product launches. RAND
Journal of Economics , in press.